Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.65 |
| ▸ | TP53 | P04637 | 2/20 | 0.63 |
| ▸ | POLB | P06746 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | APEX1 | P27695 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 2/20 | 0.55 |
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | CA3 | P07451 | 2/20 | 0.55 |
| ▸ | CA4 | P22748 | 2/20 | 0.55 |
| ▸ | CA6 | P23280 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL629408 | 0.86 | CA1 (0.62) | SMN1; SMN2TP53POLBMEN1KMT2A | |
| SCHEMBL21222557 | 0.84 | TP53 (0.66) | SMN1; SMN2TP53POLBMEN1KMT2A | |
| SCHEMBL5632654 | 0.81 | TP53 (0.61) | SMN1; SMN2TP53POLBMEN1KMT2A | |
| SCHEMBL10626835 | 0.80 | TP53 (0.71) | SMN1; SMN2TP53POLBTDP1ALDH1A1 | |
| SCHEMBL8736369 | 0.79 | TP53 (0.59) | SMN1; SMN2TP53POLBMEN1KMT2A | |
| SCHEMBL9740903 | 0.78 | SMN1; SMN2 (0.55) | SMN1; SMN2TP53POLBMEN1KMT2A | |
| SCHEMBL12599386 | 0.78 | CA1 (0.58) | SMN1; SMN2TP53POLBMEN1KMT2A | |
| SCHEMBL3523296 | 0.78 | TP53 (0.58) | SMN1; SMN2TP53POLBMEN1KMT2A | |
| SCHEMBL9290603 | 0.78 | POLB (0.66) | SMN1; SMN2TP53POLBMEN1KMT2A | |
| SCHEMBL8246439 | 0.77 | SMN1; SMN2 (0.53) | SMN1; SMN2TP53POLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3419974-B1 | PROCESS FOR THE SEPARATION OF ENANTIOMERS OF PIPERAZINE DERIVATIVES | ASCENEURON SA (CH) | 2021-05-05 | — | — | EP | disclosed |
| EP-3419976-B1 | ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES | ASCENEURON SA (CH) | 2021-04-07 | — | — | EP | disclosed |
| WO-2020039029-A1 | SPIRO COMPOUNDS AS GLYCOSIDASE INHIBITORS | ASCENEURON S. A. (CH) | 2020-02-27 | — | — | WO | disclosed |
| WO-2020039027-A1 | PYRROLIDINE GLYCOSIDASE INHIBITORS | ASCENEURON S. A. (CH) | 2020-02-27 | — | — | WO | disclosed |
| WO-2020039028-A1 | TETRAHYDRO-BENZOAZEPINE GLYCOSIDASE INHIBITORS | ASCENEURON S. A. (CH) | 2020-02-27 | — | — | WO | disclosed |
| EP-3556757-A1 | CYCLOALKYL-LINKED DIHETEROCYCLE DERIVATIVES | Pfizer Inc (US) | 2019-10-23 | — | — | EP | disclosed |
| WO-2019037860-A1 | LINEAR GLYCOSIDASE INHIBITORS | Asceneuron S.A. (CH) | 2019-02-28 | — | — | WO | disclosed |
| US-9956302-B2 | Compounds and compositions for the treatment of ocular disorders | Graybug Vision, Inc. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20180110864-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2018-04-26 | — | — | US | disclosed |
| US-20180104350-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2018-04-19 | — | — | US | disclosed |
| US-7129249-B2 | Heterocyclic amide derivatives as inhibitors of glycogen phoshorylase | ASTRAZENECA AB (SE) | 2006-10-31 | — | — | US | disclosed |
| WO-2005054430-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-06-16 | — | — | WO | disclosed |
| US-20050131016-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2005-06-16 | — | — | US | disclosed |
| US-20050131015-A1 | Heterocyclic amide derivatives as inhibitors of glycogen phoshorylase | ASTRAZENECA AB (SE) | 2005-06-16 | — | — | US | disclosed |
| EP-1485371-A2 | INDOLE AMIDE DERIVATIVES AND THEIR USE AS GLYCOGEN PHOSPHORYLASE INHIBITORS | AstraZeneca AB (SE) | 2004-12-15 | — | — | EP | disclosed |
| WO-2004094452-A2 | MACROCYCLIC ISOQUINOLINE PEPTIDE INHIBITORS OF HEPATITIS C VIRUS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2003099316-A1 | HETEROCYCLICSULFONAMIDE HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-04 | — | — | WO | disclosed |
| WO-2003074513-A2 | INDOLE AMIDE DERIVATIVES AND THEIR USE AS GLYCOGEN PHOSPHORYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2003-09-12 | — | — | WO | disclosed |
| US-5654322-A | HYPOTENSIVE AGENTS, CEREBRAL APOPLEXY | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1997-08-05 | — | — | US | disclosed |
| EP-0656355-A1 | BIPHENYLMETHANE DERIVATIVE AND MEDICINE CONTAINING THE SAME | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1995-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131015-A1 | Heterocyclic amide derivatives as inhibitors of glycogen phoshorylase | PYGL, GYS2, GYS1 | SMN1; SMN2 2993/4885TP53 3289/4885POLB 2153/4885 |
| US-20050131016-A1 | Chemical compounds | PYGL, GYS1, CA9 | SMN1; SMN2 1573/4885TP53 3313/4885POLB 824/4885 |
| US-20180110864-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | PTGIR, PTGIS, CA2 | SMN1; SMN2 3728/4885TP53 3168/4885POLB 3189/4885 |
| US-20180104350-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | PTGIR, PTGIS, CA2 | SMN1; SMN2 3728/4885TP53 3168/4885POLB 3189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.